MetaCap

Elutia Inc. Class A (ELUT)

NASDAQ: ELUTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.9001+0.0901 (+11.12%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ELUT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$39.96M
EPS (TTM)
-$0.68
52-week range
0.50 – 1.39
Day range
0.7908 – 0.9199
Volume / Avg
83.28K / 185.17K
Beta
—

52-week range

$0.50$1.39

ELUT stock today

Shares of Elutia (ELUT) finished higher on Nov 20 at $0.9001, a gain of 11.12% or $0.0901 per share, versus the S&P 500's 3.70% decline. Trading was light, with 83.28K shares changing hands, about 45% of the average daily volume. At this level, ELUT sits in the middle of its 52-week range of $0.50 to $1.39: 35.0% below the high, set on Mar 4, 2026 and 80.0% above the low.

ELUT is up 29.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.6%. Elutia has posted a net loss over the last twelve months (EPS of -$0.68), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Elutia

Company profile

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. C. Randal Mills Ph.D.
Headquarters
Gaithersburg, MD
Employees
25
IPO year
2020
Website
elutia.com

Financial highlights

Full financials

In fiscal 2025, Elutia generated $12.3 million in revenue, down 15.0% from fiscal 2024, its first annual decline since 2024. Net income was $53.4 million, for a net margin of 434.2% versus a median of -137.9% in the prior 5 years. Gross margin was 53.7% (up from 46.4%) and operating margin -218.9%.

Elutia annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$12.29M$14.47M$24.75M$23.85M$47.39M
Growth-15.03%-41.54%+3.76%-49.68%+11.03%
Net income$53.38M$-53.95M$-37.66M$-32.90M$-24.83M
EPS (diluted)$0.87$-1.86$-2.07$-2.38$-2.38

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

Avg. price target

$5.00+455.49%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.01 vs —

ELUT news

All ELUT news

Elutia peers

Health Care sector
ELUT peer companies
CompanyPrice% ChgMarket capCompare
INKTMiNK Therapeutics Inc.8.02-6.85%$41.17Mvs ELUT
ELOXEloxx Pharmaceuticals Inc.10.69-1.75%$43.69Mvs ELUT
GRMLGreenland Mines Ltd.2.99+2.75%$44.31Mvs ELUT
TILInstil Bio Inc.5.23-5.77%$35.47Mvs ELUT
IMAImageneBio Inc.3.920.00%$48.83Mvs ELUT
CRBUCaribou Biosciences Inc.0.2843-8.44%$30.71Mvs ELUT
KLRSKalaris Therapeutics Inc.1.28-5.19%$30.47Mvs ELUT
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs ELUT

Indexes, lists and sector

Elutia stock FAQ

What is Elutia's stock price today?

ELUT last traded at $0.9001 as of Nov 20, 4:00 PM EST, up 11.12% on the day. Prices are delayed at least 15 minutes.

Who is Elutia's CEO?

Dr. C. Randal Mills Ph.D. is the chief executive officer of Elutia Inc. Class A, which has about 25 employees.

What is the ELUT 52-week high?

The 52-week high for ELUT is $1.39 and the 52-week low is $0.50. The stock is currently 35.0% below its high.

Compare ELUT